Table 1.
Independent prognostic factors for OS of AML patients in TCGA cohort.
| AML patients with intermediate and adverse-cytogenetic risk | Non-M3 AML patients | |||||
|---|---|---|---|---|---|---|
| No. of patients | HR(95%CI) | P value | No. of patients | HR(95%CI) | P value | |
| IPM | ||||||
| IPM-LR | 87 | 1.00 | < 0.0001 | 104 | 1.00 | < 0.0001 |
| IPM-HR | 20 | 3.22 (1.71–6.05) | 22 | 3.40 (1.84–6.27) | ||
| Age | ||||||
| Age < 60y | 52 | 1.00 | 0.040 | 60 | 1.00 | 0.030 |
| Age ≥ 60y | 55 | 1.71 (1.03–2.85) | 66 | 1.72 (1.06–2.81) | ||
| TP53 | ||||||
| Wild type | 97 | 1.00 | 0.001 | 114 | 1.00 | < 0.0001 |
| Mutation | 10 | 4.05 (1.82–9.0) | 10 | 4.26 (2.0–9.06) | ||
| FLT3-ITD | ||||||
| ( −) | 86 | 1.00 | 0.033 | 99 | 1.00 | 0.027 |
| ( +) | 21 | 1.94 (1.06–3.58) | 25 | 1.95 (1.08–3.52) | ||
| DNMT3A | ||||||
| Wild type | 74 | 1.00 | 0.006 | 90 | 1.00 | 0.006 |
| Mutation | 33 | 2.07 (1.23–3.48) | 34 | 2.08 (1.24–3.50) | ||